AlphaQuest LLC Buys New Holdings in NeuroPace, Inc. $NPCE

AlphaQuest LLC purchased a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,380 shares of the company’s stock, valued at approximately $82,000.

A number of other large investors also recently modified their holdings of the company. Jump Financial LLC purchased a new stake in shares of NeuroPace during the 1st quarter worth about $154,000. Petrus Trust Company LTA acquired a new position in NeuroPace during the first quarter valued at approximately $165,000. Birchview Capital LP grew its stake in NeuroPace by 64.4% during the first quarter. Birchview Capital LP now owns 16,442 shares of the company’s stock worth $202,000 after buying an additional 6,442 shares during the period. Corton Capital Inc. purchased a new stake in NeuroPace during the first quarter worth approximately $203,000. Finally, Rhumbline Advisers increased its position in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock worth $212,000 after acquiring an additional 2,267 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NPCE has been the topic of several recent research reports. Leerink Partners restated an “outperform” rating and set a $19.00 target price on shares of NeuroPace in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, October 8th. Zacks Research downgraded NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Wells Fargo & Company increased their target price on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of NeuroPace in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

NeuroPace Stock Performance

NASDAQ:NPCE opened at $12.98 on Thursday. The firm has a 50-day moving average of $10.21 and a two-hundred day moving average of $10.84. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The stock has a market cap of $429.38 million, a P/E ratio of -17.08 and a beta of 1.90. NeuroPace, Inc. has a 1-year low of $6.63 and a 1-year high of $18.98.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09. The business had revenue of $27.35 million for the quarter, compared to analysts’ expectations of $24.64 million. NeuroPace had a negative return on equity of 139.13% and a negative net margin of 25.28%. NeuroPace has set its FY 2025 guidance at EPS. On average, research analysts expect that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.